Vertex says drug reduced marker of kidney disease in late-stage trial

Vertex mentioned Monday {that a} drug it secured as a part of a $4.9 billion acquisition efficiently diminished by half a key marker of a kidney illness referred to as IgA nephropathy.

The outcomes, from a Section 3 trial, match knowledge from a examine of Otsuka’s just lately accredited Voyxact and are numerically superior to knowledge launched final 12 months by Vera Therapeutics.

All three corporations have been racing to deal with a illness that impacts 330,000 individuals throughout the U.S. and Europe, in line with Vertex’s estimates, placing many vulnerable to creating end-stage renal illness. Analysts have projected Vertex’s drug may finally usher in $4 billion or extra in annual gross sales.